Impairment Clinical Trials

656 recruitingLast updated: June 17, 2026

There are 656 actively recruiting impairment clinical trials across 56 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, San Antonio, Texas, United States, Orlando, Florida, United States. Updated daily from ClinicalTrials.gov.


Impairment Trials at a Glance

656 actively recruiting trials for impairment are listed on ClinicalTrialsFinder across 6 cities in 56 countries. The largest study group is Not Applicable with 352 trials, with the heaviest enrollment activity in New York, San Antonio, and Orlando. Lead sponsors running impairment studies include Johns Hopkins University, University of Alabama at Birmingham, and Riphah International University.

Browse impairment trials by phase

Treatments under study

About Impairment Clinical Trials

Looking for clinical trials for Impairment? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Impairment trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Impairment clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 656 trials

Recruiting
Not Applicable

e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most

DementiaMild Cognitive Impairment (MCI)Potentially Inappropriate Medication Use
Johns Hopkins University100 enrolled1 locationNCT07454824
Recruiting
Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

HealthyMild Cognitive ImpairmentAlzheimer s Disease
National Institute of Mental Health (NIMH)90 enrolled1 locationNCT07169630
Recruiting

Phrenic Infiltration as Cryoanalgesia Adjuvant for Early Postoperative Pain Following the Nuss Procedure

Pectus excavatumCryo AnalgesiaPhrenic Nerve-related Diaphragmatic Impairment
Papa Giovanni XXIII Hospital50 enrolled1 locationNCT07290582
Recruiting
Phase 1

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

Renal Impairment
Incyte Corporation16 enrolled2 locationsNCT07559396
Recruiting
Phase 2

CBD for Individuals at Risk for Alzheimer's Disease

Mild Cognitive Impairment
University of Colorado, Denver236 enrolled1 locationNCT05822362
Recruiting
Not Applicable

Using Light Therapy for Mild Cognitive Impairment

Mild Cognitive Impairment (MCI)Amyloid Pathology
University of Oklahoma40 enrolled1 locationNCT07651787
Recruiting
Not Applicable

The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment

Type 2 Diabetes Mellitus (T2DM)Mild Cognitive Impairment (MCI)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School40 enrolled1 locationNCT07650318
Recruiting
Not Applicable

Music for Pain and Dementia

DementiaCaregiverAlzheimer Disease+2 more
Yale University60 enrolled1 locationNCT07602283
Recruiting
Phase 1

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

Healthy VolunteersHepatic Impairment
Bristol-Myers Squibb24 enrolled3 locationsNCT07248839
Recruiting
Not Applicable

An Ecological Momentary Intervention for the Reduction of Impairment in Somatic Symptom Disorder

Somatic Symptom Disorder (DSM-5)Persistent Physical SymptomsMedically Unexplained Symptoms+2 more
University of Vienna40 enrolled1 locationNCT07646509
Recruiting
Phase 1

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting

The Proactive Ophthalmic Examination Cohort

Eye DiseasesVision Impairment
Zhongshan Ophthalmic Center, Sun Yat-sen University5,000 enrolled1 locationNCT05851287
Recruiting
Not Applicable

Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment

FTDAD - Alzheimer's DiseaseAD-MCI+1 more
Tianjin Huanhu Hospital60 enrolled1 locationNCT07643363
Recruiting
Phase 1

Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals24 enrolled5 locationsNCT07422610
Recruiting
Phase 1

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting

InRAD Observational Study

Mild Cognitive Impairment (MCI)Alzheimer's Disease(AD)Subjective Cognitive Decline (SCD)+1 more
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation50,000 enrolled2 locationsNCT07213700
Recruiting

Dementia With Lewy Bodies: Clinical Symptoms, Biomarkers and Progression

Mild Cognitive Impairment (MCI)Other DementiasCognitively Unimpaired+1 more
Karolinska Institutet600 enrolled1 locationNCT07629349
Recruiting
Phase 2

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Alzheimer DiseaseMild Cognitive Impairment (MCI)Subjective Cognitive Decline (SCD)
Massachusetts General Hospital40 enrolled1 locationNCT07236190
Recruiting
Phase 1

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

Severe Hepatic ImpairmentNormal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)20 enrolled3 locationsNCT07250633
Recruiting
Not Applicable

Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke

Chonic Stroke Patients With Motor Impairment of Upper Limb
Institut National de la Santé Et de la Recherche Médicale, France50 enrolled1 locationNCT06951035